Key Takeaways Rapport shares surged after RAP-219 met goals in a phase IIa study for focal onset seizures.Treatment with the candidate cut seizure frequency, with 24% of patients achieving seizure freedom.Plans include FDA talks in 2025 and pivotal epilepsy studies starting in 2026.Shares of Rapport Therapeutics (RAPP) surged 61.6% in a week after the company reported positive top-line data from a mid-stage study of its lead candidate, RAP-219, in patients with drug-resistant focal onset seizures (FOS), a t ...

BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in the following upcoming investor conference. TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit (virtual) – fireside chat on W ...

Rapport stock (NASDAQ: RAPP) cratered 18% on Wednesday as the market delivered a harsh verdict on its latest funding strategy. The catalyst was as predictable as it was painful. ...

Core Viewpoint - Rapport Therapeutics, Inc. has announced a public offering of 9,615,385 shares at a price of $26.00 per share, aiming to raise approximately $250 million in gross proceeds before expenses [1][3]. Company Overview - Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders [5]. - The company utilizes a RAP technology platform based on pioneering discoveries related to receptor associated proteins (RAPs) in the brain, which allows for a differentiated approach in drug discovery [5]. - The lead investigational drug, RAP-219, targets specific regions of the brain and is being pursued for conditions such as drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain [5]. Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 1,442,307 shares at the public offering price [1]. - The offering is expected to close around September 11, 2025, pending customary closing conditions [1]. - Goldman Sachs, Jefferies, TD Cowen, and Stifel are acting as joint book-running managers for the offering [2].

BOSTON and SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Rapport. In addition, R ...

Rapport stock (NASDAQ: RAPP) exploded on Monday, climbing nearly 200% in just one trading session. The jump came after a mix of excitement over upcoming clinical trial data and growing confidence that... ...

Rapport Therapeutics Conference Call Summary Company Overview - **Company**: Rapport Therapeutics (NasdaqGM:RAPP) - **Focus**: Development of RAP-219 for focal onset seizures and other indications Key Industry Insights - **Market Need**: Despite over 30 approved anti-seizure medications, up to 40% of patients continue to experience seizures, indicating a significant unmet need in the focal epilepsy market [5][6] - **Potential Market Size**: RAP-219 is believed to represent a multi-billion dollar commercial opportunity, subject to approval [6][19] Core Findings from the Phase 2A Trial of RAP-219 - **Efficacy Results**: - 78% reduction in clinical seizure frequency [4][14] - 24% seizure freedom rate [4][23] - 71% median reduction in long episode frequency from baseline [12] - 85.2% of patients achieved a 30% or greater reduction in long episodes [13] - 72% of patients achieved a 50% or greater reduction in clinical seizures [15] - **Safety Profile**: RAP-219 was generally well tolerated, with common treatment-emergent adverse events (TEAEs) being dizziness, headache, and fatigue [16] - **Dosing Convenience**: Once-daily dosing and low risk of drug-drug interactions enhance the potential for widespread adoption among healthcare providers [6][18] Development Plans and Future Steps - **Next Steps**: Plans to meet with the FDA for an end-of-Phase 2 meeting in Q4 2025 and initiate Phase 3 trials in Q3 2026 [17][19] - **Long-Acting Injectable (LAI)**: Development of an LAI formulation is ongoing, which could improve patient adherence and expand clinical utility [18] - **Bipolar Mania Trials**: Ongoing Phase 2 trial in bipolar mania, with expectations for data in early 2027 [52] Additional Insights - **Physician Feedback**: Positive reception from physicians regarding RAP-219's profile, with expectations for it to be used in both refractory settings and earlier in treatment algorithms [64][66] - **Translatability to Phase 3**: Confidence in the translatability of Phase 2 results to Phase 3 trials, with a baseline seizure frequency of 10 being representative of typical disease burden [22][24] - **Market Dynamics**: The competitive context and the drug's profile are expected to facilitate efficient patient recruitment for Phase 3 trials [41][42] Conclusion - RAP-219 demonstrates promising efficacy and safety profiles, positioning it as a potential best-in-class treatment for focal onset seizures and possibly other indications. The company is well-prepared to advance its development plans and capitalize on the significant market opportunity.

RAP-219 Phase 2a Trial in Drug-resistant Focal Onset Seizures Topline Results Conference Call Presentation September 8, 2025 Disclaimer This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and simil ...

Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving seizure freedom for the 8-week treatment period (p<0.0001)Data support advancement of RAP-219 into Phase 3 registrational trialsCompany to host a conference call today at 8:00 a.m. ET BOSTON and SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”) ...

BOSTON and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a conference call and live webcast at 8:00 am ET on September 8, 2025, to report topline results for the Phase 2a trial of RAP-219 in patients with drug-resistant focal ons ...